AGN194204 IRX4204; NRX194204; VTP 194204|cas:220619-73-8|西域试剂

AGN194204 IRX4204; NRX194204; VTP 194204,99.0%

产品编号：Bellancom-13717| CAS NO：220619-73-8| 分子式：C₂₄H₃₂O₂| 分子量：352.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-13717		￥5000.00	杭州北京（现货）
Bellancom-13717		￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AGN194204 IRX4204; NRX194204; VTP 194204

产品介绍

AGN194204 (IRX4204) 是一种具有口服活性的，选择性 RXR 激动剂，对 RXRα，RXRβ 和 RXRγ 的 K_d 值分别为 0.4 nM，3.6 nM 和 3.8 nM，EC₅₀ 分别为 0.2 nM，0.8 nM 和 0.08 nM。AGN194204 对 RAR 无活性，并具有抗炎和抗癌作用。

生物活性

AGN194204 (IRX4204) is an orally active and selective RXR agonist with K_d values 0.4 nM, 3.6 nM and 3.8 nM and EC₅₀s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα, RXRβ and RXRγ, respectively. AGN194204 is inactive against RAR. AGN194204 has anti-inflammatory and anticarcinogenic actions.

体外研究

AGN194204 (NRX194204; 0-100 nM; 24 hours; E, RAW cells) treatment blocks the ability of lipopolysaccharide and tumor necrosis factor-α to induce the release of nitric oxide and interleukin 6 and the degradation of IKBα in RAW264.7 macrophage-like cells.
AGN194204 (NRX194204; 1 μM; 72 hours; SK-BR-3 human breast cancer cells) treatment induces apoptosis in breast cancer cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	SK-BR-3 human breast cancer cells
Concentration:	1 μM
Incubation Time:	72 hours
Result:	Induced apoptosis in lung and breast cancer cells.

Western Blot Analysis

Cell Line:	E, RAW cells
Concentration:	0 nM, 1 nM, 10 nM and 100 nM
Incubation Time:	24 hours
Result:	Blocked the ability of lipopolysaccharide and tumor necrosis factor-α to induce the release of nitric oxide and interleukin 6 and the degradation of IKBα in RAW264.7 macrophage-like cells.

体内研究
(In Vivo)

AGN194204 (NRX194204; 30-60 mg/kg; oral administration; daily; for 15 weeks; female A/J mice) treatment significantly reduces the number and size of tumors on the surface of the lungs and reduces the total tumor volume per slide by 64% to 81% compared with the control group.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female A/J mice with vinyl carbamate
Dosage:	30 mg/kg, 60 mg/kg
Administration:	Oral administration; daily; for 15 weeks
Result:	Significantly reduced the number and size of tumors on the surface of the lungs and reduced the total tumor volume per slide by 64% to 81% compared with the control group.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female A/J mice with vinyl carbamate
Dosage:	30 mg/kg, 60 mg/kg
Administration:	Oral administration; daily; for 15 weeks
Result:	Significantly reduced the number and size of tumors on the surface of the lungs and reduced the total tumor volume per slide by 64% to 81% compared with the control group.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female A/J mice with vinyl carbamate
Dosage:	30 mg/kg, 60 mg/kg
Administration:	Oral administration; daily; for 15 weeks
Result:	Significantly reduced the number and size of tumors on the surface of the lungs and reduced the total tumor volume per slide by 64% to 81% compared with the control group.